Pathogenic somatic variants of PRKACA often manifest as endocrine and metabolic disorders such as Cushing’s syndrome, cortisol-producing adenomas (CPA’s), hypothalamic hamartomas, and cardiac myxomas [83–88]. Here, PRKACA is linked to Cushing syndrome.